JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

Home・Akcijų sąrašas・Ardelyx Inc

Search

Ardelyx Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

6.88 8.69

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.82

Max

7.04

Pagrindiniai rodikliai
By Trading Economics
Pajamos	562K -407K
Pardavimai	15M 125M
Pelnas, tenkantis vienai akcijai	-0.002
Pelno marža	-0.325
Darbuotojai	489
EBITDA	4.5M 10M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+141.28% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-200M 1.5B
Ankstesnė atidarymo kaina	-1.81
Ankstesnė uždarymo kaina	6.88

Naujienos nuotaikos

By Acuity

55%

45%

292 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.62 / 3.95 Palaikymas ir pasipriešinimas

Ardelyx Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-04 22:17; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

2026-05-04 23:47; UTC

Uždarbis

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

2026-05-04 23:45; UTC

Uždarbis

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

2026-05-04 23:40; UTC

Rinkos pokalbiai

Gold Steady Amid Likely Technical Recovery -- Market Talk

2026-05-04 22:44; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Jim Beyer To Be Chief Executive of Combined Company

2026-05-04 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

2026-05-04 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

2026-05-04 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Pro Forma Market Capitalization About A$10.7 Billion

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Shareholders to Own About 51% of Combined Company

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Board Unanimously Endorsed, Supported Deal

2026-05-04 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Deal Unanimously Recommended by Vault Board

2026-05-04 22:39; UTC

Įsigijimai, susijungimai, perėmimai

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources to Acquire All Ordinary Shares in Vault

2026-05-04 22:38; UTC

Įsigijimai, susijungimai, perėmimai

Regis Resources, Vault Minerals Agree to Merger of Equals

2026-05-04 22:37; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

2026-05-04 22:26; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

2026-05-04 22:02; UTC

Uždarbis

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

2026-05-04 22:00; UTC

Rinkos pokalbiai

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

2026-05-04 21:52; UTC

Uždarbis

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Some Sectors More Affected Than Others>WBC.AU

2026-05-04 21:50; UTC

Uždarbis

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

2026-05-04 21:49; UTC

Uždarbis

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

2026-05-04 21:44; UTC

Uždarbis

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

2026-05-04 21:43; UTC

Uždarbis

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

2026-05-04 21:41; UTC

Uždarbis

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

2026-05-04 21:40; UTC

Uždarbis

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Akcijų palyginimas

Kainos pokytis

Ardelyx Inc Prognozė

Kainos tikslas

By TipRanks

141.28% į viršų

12 mėnesių prognozė

Vidutinis 16.6 USD 141.28%

Aukščiausias 19 USD

Žemiausias 13 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ardelyx Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Remiantis 5 analitikų, pateikusių Ardelyx Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.62 / 3.95Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

292 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Kitos sektoriaus akcijos

JNJ

Johnson and Johnson

225.55

UNH

UnitedHealth Group Inc

364.08

TMO

Thermo Fisher Scientific Inc

465.22

ISRG

Intuitive Surgical Inc

452.75

ABT

Abbott Laboratories

87.25

Live chat